Physician

Nabeel Sarhill, MD

According to 2025 Medicare claims, Nabeel Sarhill, MD (NPI: 1811098304) practices hematology/oncology in the Brownsville-Harlingen, TX market, with the plurality of this provider's patient population coming from Cameron, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 78550-8321.

Sarhill's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 633 traditional Medicare patients, billed 96,286 HCPCS/CPT codes, and received $1,248,876 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,228 prescription claims across 450 beneficiaries totaling $7,264,772 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 41 claims. Open Payments data shows 39 records totaling $971. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,639,328 and ending at $1,248,876. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,836,276 to $7,264,772. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	656	125,965	$1,639,328
2016	680	117,075	$1,691,063
2017	801	110,576	$1,655,545
2018	834	126,489	$1,744,376
2019	785	140,509	$2,188,977
2020	749	106,779	$1,711,487
2021	692	77,420	$1,181,525
2022	691	104,096	$1,687,534
2023	643	115,312	$1,371,957
2024	633	96,286	$1,248,876

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	316	1,770	$1,836,276
2016	342	1,764	$1,853,814
2017	329	1,703	$1,829,122
2018	354	1,744	$2,726,470
2019	391	1,929	$4,499,053
2020	344	1,724	$4,901,118
2021	349	1,902	$6,106,240
2022	392	1,942	$6,734,945
2023	418	2,005	$6,025,313
2024	450	2,228	$7,264,772

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	237	$15,273
2016	N/R	35	$1,383
2017	N/R	N/R	N/R
2018	N/R	35	$4,112
2019	N/R	N/R	N/R
2020	N/R	41	$4,171
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	382	721	$87
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	158	580	$57
80053	Blood test, comprehensive group of blood chemicals	396	826	$10
36415	Insertion of needle into vein for collection of blood sample	352	918	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	399	1,025	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	144	3,969	$2,360,658
Lenvima	Lenvatinib Mesylate	22	690	$527,327
Tasigna	Nilotinib Hcl	25	700	$511,533
Brukinsa	Zanubrutinib	33	990	$471,543
Lonsurf	Trifluridine/Tipiracil Hcl	33	924	$371,719

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	39	$971	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nabeel Sarhill, MD?

Tedicare shows public-source Medicare data for Nabeel Sarhill, MD (NPI 1811098304), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nabeel Sarhill, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Nabeel Sarhill, MD?

Nabeel Sarhill, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Nabeel Sarhill, MD have Open Payments data?

Nabeel Sarhill, MD has 39 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.